Breaking down bone: New insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases

Research output: Contribution to journalReview article

35 Scopus citations


Bone metastases are the most common skeletal complication of malignancy. Tumor cells disrupt normal bone remodeling to promote bone destruction and its associated morbidity. In the August 15, 2009, issue of Genes & Development, Lu and colleagues (pp. 1882-1894) propose a novel molecular mechanism by which tumor-produced metalloproteinases release epidermal growth factor (EGF) ligands to activate the central osteoclastogenic pathway receptor activator of NF-κB ligand (RANKL) to promote breast cancer osteolysis. This work has important therapeutic applications that may quickly translate to more effective treatment for bone metastases.

Original languageEnglish (US)
Pages (from-to)2117-2123
Number of pages7
JournalGenes and Development
Issue number18
StatePublished - Sep 15 2009



  • Bone metastasis
  • Breast cancer
  • EGFR
  • Metalloprotease
  • Osteoclastogenesis

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology

Cite this